Coronary heart disease secondary prevention weight management
|
Coronary heart disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Coronary heart disease secondary prevention weight management On the Web |
|
American Roentgen Ray Society Images of Coronary heart disease secondary prevention weight management |
|
FDA on Coronary heart disease secondary prevention weight management |
|
CDC on Coronary heart disease secondary prevention weight management |
|
Coronary heart disease secondary prevention weight management in the news |
|
Blogs on Coronary heart disease secondary prevention weight management |
|
Risk calculators and risk factors for Coronary heart disease secondary prevention weight management |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Weight Management
- If waist circumference is >35 inches in women and >40 inches in men, initiate lifestyle changes and consider treatment strategies for metabolic syndrome as indicated.
- The initial goal of weight loss therapy should be to reduce body weight by approximately 5-10 percent from baseline or to achieve
2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease (DO NOT EDIT) [1]
Weight Management (DO NOT EDIT) [1]
| “ | Goal: Body mass index of 18.5 to 24.9 kg/m2; Waist circumference of <35 inches (<89 cm) in women and <40 inches (<102 cm) in men. | ” |
| Class I |
| "1. Body mass index and/or waist circumference should be assessed at every visit, and the clinician should consistently encourage weight maintenance/reduction through an appropriate balance of lifestyle physical activity, structured exercise, caloric intake, and formal behavioral programs when indicated to maintain/achieve a body mass index between 18.5 and 24.9 kg/m2. [2][3][4][5][6][7][8][9][10] (Level of Evidence: B)" |
| "2. If waist circumference (measured horizontally at the iliac crest) is ≥35 inches (≥89 cm) in women and ≥40 inches (≥102 cm) in men, therapeutic lifestyle interventions should be intensified and focused on weight management. [6][7][8][9][10] (Level of Evidence: B)" |
| "3.The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from baseline. With success, further weight loss can be attempted if indicated. (Level of Evidence: C)" |
Sources
- 2011 AHA/ACCF Guidelines for Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Aterosclerotic Vascular Disease (DO NOT EDIT) [1]
References
- ↑ 1.0 1.1 1.2 Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA; et al. (2011). "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation". Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934.
- ↑ "Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health". Obes. Res. 6 Suppl 2: 51S–209S. 1998. PMID 9813653. Unknown parameter
|month=ignored (help) - ↑ Klein S, Burke LE, Bray GA; et al. (2004). "Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation". Circulation. 110 (18): 2952–67. doi:10.1161/01.CIR.0000145546.97738.1E. PMID 15509809. Unknown parameter
|month=ignored (help) - ↑ Grundy SM, Cleeman JI, Daniels SR; et al. (2005). "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary". Crit Pathw Cardiol. 4 (4): 198–203. PMID 18340209. Unknown parameter
|month=ignored (help) - ↑ Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW (1999). "Body-mass index and mortality in a prospective cohort of U.S. adults". N. Engl. J. Med. 341 (15): 1097–105. doi:10.1056/NEJM199910073411501. PMID 10511607. Unknown parameter
|month=ignored (help) - ↑ 6.0 6.1 Jensen MK, Chiuve SE, Rimm EB; et al. (2008). "Obesity, behavioral lifestyle factors, and risk of acute coronary events". Circulation. 117 (24): 3062–9. doi:10.1161/CIRCULATIONAHA.107.759951. PMID 18541738. Unknown parameter
|month=ignored (help) - ↑ 7.0 7.1 Arnlöv J, Ingelsson E, Sundström J, Lind L (2010). "Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men". Circulation. 121 (2): 230–6. doi:10.1161/CIRCULATIONAHA.109.887521. PMID 20038741. Unknown parameter
|month=ignored (help) - ↑ 8.0 8.1 Lavie CJ, Milani RV, Ventura HO (2009). "Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss". J. Am. Coll. Cardiol. 53 (21): 1925–32. doi:10.1016/j.jacc.2008.12.068. PMID 19460605. Unknown parameter
|month=ignored (help) - ↑ 9.0 9.1 Gruberg L, Weissman NJ, Waksman R; et al. (2002). "The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?". J. Am. Coll. Cardiol. 39 (4): 578–84. PMID 11849854. Unknown parameter
|month=ignored (help) - ↑ 10.0 10.1 Jacobs EJ, Newton CC, Wang Y; et al. (2010). "Waist circumference and all-cause mortality in a large US cohort". Arch. Intern. Med. 170 (15): 1293–301. doi:10.1001/archinternmed.2010.201. PMID 20696950. Unknown parameter
|month=ignored (help)